Literature DB >> 31479696

Ursodeoxycholic acid in pregnancy?

Elsemieke de Vries1, Ulrich Beuers2.   

Abstract

The case of a 34-year-old woman with primary biliary cholangitis (PBC) before, during and after pregnancy is described. The use of ursodeoxycholic acid (UDCA) during and after pregnancy is discussed. UDCA has not been approved by the drug regulatory authorities as a pregnancy-safe drug; therefore, the reluctance of clinicians to prescribe UDCA during pregnancy is understandable. This Grand Round aims to provide a detailed analysis of the current evidence, safety data and clinical experience with UDCA (and alternative drugs) during pregnancy and lactation. Based on this analysis, advice for clinicians regarding the use of UDCA during pregnancy and lactation is given.
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lactation; PBC; PSC; Primary biliary cholangitis; Primary sclerosing cholangitis; Stillbirth; UDCA

Mesh：

Substances：

Year:  2019        PMID： 31479696     DOI： 10.1016/j.jhep.2019.08.020

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


  3 in total

1.  Ursodeoxycholic acid improves pregnancy outcome in patients with intrahepatic cholestasis during pregnancy: A protocol for systematic review and meta-analysis.

Authors:  Yan Wang; Xiabiao Peng; Yongyuan Zhang; Qiuchen Yang; Yuhong Xiao; Yuezhou Chen
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

2.  The Effect of Tauroursodeoxycholic Acid (TUDCA) Treatment on Pregnancy Outcomes and Vascular Function in a Rat Model of Advanced Maternal Age.

Authors:  Mazhar Pasha; Raven Kirschenman; Amy Wooldridge; Floor Spaans; Christy-Lynn M Cooke; Sandra T Davidge
Journal:  Antioxidants (Basel)       Date:  2022-06-28

3.  APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.

Authors:  Hong You; Xiong Ma; Cumali Efe; Guiqiang Wang; Sook-Hyang Jeong; Kazumichi Abe; Weijia Duan; Sha Chen; Yuanyuan Kong; Dong Zhang; Lai Wei; Fu-Sheng Wang; Han-Chieh Lin; Jin Mo Yang; Tawesak Tanwandee; Rino A Gani; Diana A Payawal; Barjesh C Sharma; Jinlin Hou; Osamu Yokosuka; A Kadir Dokmeci; Darrell Crawford; Jia-Horng Kao; Teerha Piratvisuth; Dong Jin Suh; Laurentius A Lesmana; Jose Sollano; George Lau; Shiv K Sarin; Masao Omata; Atsushi Tanaka; Jidong Jia
Journal:  Hepatol Int       Date:  2022-02-04       Impact factor: 6.047
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.